Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
39.55
-0.17 (-0.43%)
At close: Jan 16, 2026, 4:00 PM EST
39.92
+0.37 (0.94%)
After-hours: Jan 16, 2026, 7:42 PM EST
Royalty Pharma Employees
Royalty Pharma had 99 employees as of December 31, 2024. The number of employees increased by 10 or 11.24% compared to the previous year.
Employees
99
Change (1Y)
10
Growth (1Y)
11.24%
Revenue / Employee
$23,735,798
Profits / Employee
$7,726,828
Market Cap
22.83B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 99 | 10 | 11.24% |
| Dec 31, 2023 | 89 | 14 | 18.67% |
| Dec 31, 2022 | 75 | 9 | 13.64% |
| Dec 31, 2021 | 66 | 15 | 29.41% |
| Dec 31, 2020 | 51 | 16 | 45.71% |
| Dec 31, 2019 | 35 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RPRX News
- 5 days ago - Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
- 7 days ago - Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 days ago - Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - GlobeNewsWire
- 10 days ago - Royalty Pharma Announces Dividend Increase - GlobeNewsWire
- 20 days ago - Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones - GlobeNewsWire
- 4 weeks ago - Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - GlobeNewsWire
- 6 weeks ago - Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - GlobeNewsWire